We are committed to advancing water quality testing and monitoring to help our CWS partners help their customers realize the promise of clean water with greater ease and efficiency.
At its core, the work we do at 12-15 Molecular Diagnostics is focused on two goals: (1) discover, develop and commercialize next-generation testing and diagnostics solutions, and (2) partner and collaborate with leading companies and institutions to realize the full potential of cutting-edge nanotechnology to improve safety, early interventions and the quality of people’s lives.
Dr. Saion Sinha has been leading cutting edge research into difficult scientific problems since he was a student studying physics at the Indian Institute of Technology in Kharagpur, India. He received his PhD from the University of Kentucky and serves as a professor and researcher at the University of New Haven.
After developing tests for Lyme disease and pioneering a patent for the use of carbon nanowire in testing DNA, Dr. Sinha founded 12-15 Molecular Diagnostics in 2018. The organization has studied a range of airborne disease and viruses in animals.
In 2018, the 12-15 team developed the advanced technique of hybridization, which uses carbon-based nanomaterial to process biofluids electronically. Using this technology, the 12-15 team has developed Veralize, a device that enables a 7-minute saliva test for COVID-19 with the accuracy of PCR tests.
There is a serious need for rapid testing right now. We will continue improving our technology to make a difference in people’s lives.